Kyverna Therapeutics Inc
Research Kyverna Therapeutics Inc (KYTX) on Bullrun: market cap USD 382.35M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerKYTX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 382.35M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 38.32M
- Free cash flow-USD 40.85M
Valuation Snapshot
latest market cap is USD 382.35M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 161.31M | -USD 153.72M | n/a | -3.64 | USD 124.09M | USD 29.03M | USD 232.28M |
| FY2024 | USD 0 | -USD 127.48M | -USD 116.46M | n/a | -3.33 | USD 96.62M | USD 8.24M | USD 266.59M |
| FY2023 | USD 0 | -USD 60.37M | -USD 53.03M | n/a | -89.61 | USD 34.65M | USD 9.08M | -USD 13.14M |
| FY2022 | USD 7.03M | -USD 28.89M | -USD 36.88M | n/a | -1.12 | USD 37.74M | USD 10.56M | -USD 74.00M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 382.35M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 567.67M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 161.62M | n/a | n/a | n/a |
About Kyverna Therapeutics Inc
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Kyverna Therapeutics Inc's market cap?
Kyverna Therapeutics Inc's market capitalization is USD 382.35M.
What does Kyverna Therapeutics Inc do?
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc.